VCYT Stock Analysis: Veracyte | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 3.484m USD | 12M Return: 34.9% | US92337F1075 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 50.3M
Qual. Beats: 2
Rev. Trend: 99.6%
Qual. Beats: 6
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Veracyte, Inc. (NASDAQ: VCYT) is a molecular diagnostics company headquartered in South San Francisco, California, operating in the United States and internationally. Founded in 2006 under the name Calderome, Inc., the company adopted its current name in March 2008 and went public in October 2013. It is classified within the Health Care sectors Biotechnology sub-industry, with a mid-cap market valuation.
The companys business model centers on developing and commercializing genomic classifiers and molecular tests that aid in the diagnosis and risk stratification of various cancers. Its test menu includes the Afirma Genomic Sequencing Classifier for thyroid nodules, the Decipher Prostate and Decipher Bladder Genomic Classifiers, the Prosigna Breast Cancer Assay, and the Percepta Nasal Swab Test for lung cancer. Veracyte also offers the nCounter analysis system, an instrument-based service that supports gene expression research in clinical and translational settings.
As a precision diagnostics provider, Veracyte generates revenue primarily through the sale of its proprietary tests and the licensing of its analysis platform, with growth tied to physician adoption, payer reimbursement coverage, and ongoing expansion of its oncology-focused product portfolio.
- Decipher Prostate test revenue drives double-digit segment growth
- Medicare reimbursement decisions expand covered lives and test adoption
- Acquisitions broaden oncology test menu and international footprint
| Net Income: 114.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 4.88 > 1.0 |
| NWC/Revenue: 91.13% < 20% (prev 70.60%; Δ 20.53% < -1%) |
| CFO/TA 0.12 > 3% & CFO 178.4m > Net Income 114.5m |
| Net Debt (-445.1m) to EBITDA (129.8m): -3.43 < 3 |
| Current Ratio: 9.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.2m) vs 12m ago 2.90% < -2% |
| Gross Margin: 72.09% > 18% (prev 68.26%; Δ 3.84% > 0.5%) |
| Asset Turnover: 39.70% > 50% (prev 35.65%; Δ 4.06% > 0%) |
| Interest Coverage Ratio: 100.0k > 6 (EBIT TTM 108.9m / Interest Expense TTM 1.00k) |
| A: 0.34 (Total Current Assets 574.8m - Total Current Liabilities 62.7m) / Total Assets 1.49b |
| B: -0.22 (Retained Earnings -323.4m / Total Assets 1.49b) |
| C: 0.08 (EBIT TTM 108.9m / Avg Total Assets 1.42b) |
| D: 14.17 (Book Value of Equity 1.39b / Total Liabilities 98.0m) |
| Altman-Z'' = 16.95 = AAA |
| DSRI: 0.91 (Receivables 54.2m/50.8m, Revenue 561.9m/479.1m) |
| GMI: 0.95 (GM 68.26% / 72.09%) |
| AQI: 0.89 (AQ_t 0.57 / AQ_t-1 0.65) |
| SGI: 1.17 (Revenue 561.9m / 479.1m) |
| TATA: -0.04 (NI 114.5m - CFO 178.4m) / TA 1.49b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of September 07, 2026, the stock is trading at USD 42.53 with a total of 989,834 shares traded. Over the past week, the price has changed by -1.87%, over one month by -8.36%, over three months by -14.84% and over the past year by +34.93%.
Current recommended Stop Loss: 39.90 (which is 6.2% or 1.2 ATR below the current price).
Veracyte has received a consensus analysts rating of 4.36. Therefore, it is recommended to buy VCYT.
- StrongBuy: 8
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 57.8 | 36% |
P/E Trailing = 32.3433
P/E Forward = 25.0
P/S = 6.2006
P/B = 2.62
Revenue TTM = 561.9m USD
EBIT TTM = 108.9m USD
EBITDA TTM = 129.8m USD
Long Term Debt = 34.3m USD (estimated: total debt 40.1m - short term 5.78m)
Short Term Debt = 5.78m USD (from shortTermDebt, last quarter)
Debt = 40.1m USD (from shortLongTermDebtTotal, last quarter) (leases 40.1m already included)
Net Debt = -445.1m USD (calculated: Debt 40.1m - CCE 485.2m)
Enterprise Value = 3.04b USD (3.48b + Debt 40.1m - CCE 485.2m)
Interest Coverage Ratio = 109k (Ebit TTM 108.9m / Interest Expense TTM 1.00k)
EV/FCF = 18.37x (Enterprise Value 3.04b / FCF TTM 165.5m)
FCF Yield = 5.44% (FCF TTM 165.5m / Enterprise Value 3.04b)
FCF Margin = 29.45% (FCF TTM 165.5m / Revenue TTM 561.9m)
Net Margin = 20.37% (Net Income TTM 114.5m / Revenue TTM 561.9m)
Gross Margin = 72.09% ((Revenue TTM 561.9m - Cost of Revenue TTM 156.8m) / Revenue TTM)
Gross Margin QoQ = 72.21% (prev 72.32%)
Tobins Q-Ratio = 2.04 (Enterprise Value 3.04b / Total Assets 1.49b)
Interest Expense / Debt = 0.00% (Interest Expense 1.00k / Debt 40.1m)
Taxrate = 1.41% (1.54m / 108.9m)
NOPAT = 107.4m (EBIT 108.9m * (1 - 1.41%))
Current Ratio = 9.16 (Total Current Assets 574.8m / Total Current Liabilities 62.7m)
Debt / Equity = 0.03 (Debt 40.1m / totalStockholderEquity, last quarter 1.39b)
Debt / EBITDA = -3.43 (Net Debt -445.1m / EBITDA 129.8m)
Debt / FCF = -2.69 (Net Debt -445.1m / FCF TTM 165.5m)
Total Stockholder Equity = 1.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.09% (Net Income 114.5m / Total Assets 1.49b)
RoE = 8.64% (Net Income TTM 114.5m / Total Stockholder Equity 1.33b)
RoCE = 8.01% (EBIT 108.9m / Capital Employed (Equity 1.33b + L.T.Debt 34.3m))
RoIC = 7.66% (NOPAT 107.4m / Invested Capital 1.40b)
WACC = 8.90% (E(3.48b)/V(3.52b) * Re(9.0%) + D(40.1m)/V(3.52b) * Rd(0.00%) * (1-Tc(0.01)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.39 | Cagr: 4.32%
[DCF] Terminal Value 76.22% ; FCFF base≈132.9m ; Y1≈152.3m ; Y5≈224.1m
[DCF] Fair Price = 43.81 (EV 3.08b - Net Debt -445.1m = Equity 3.52b / Shares 80.4m; r=8.90% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.21 | # QB: 2
Revenue Correlation: 99.63 | Revenue CAGR: 19.58% | SUE: 1.58 | # QB: 6
EPS current Quarter (2026-09-30): EPS=0.41 | Chg30d=-5.56% | Revisions=-75% | Analysts=11
EPS current Year (2026-12-31): EPS=1.91 | Chg30d=+5.70% | Revisions=+77% | GrowthEPS=+7.1% | GrowthRev=+14.8%
EPS next Year (2027-12-31): EPS=1.95 | Chg30d=+3.23% | Revisions=+31% | GrowthEPS=+2.2% | GrowthRev=+11.2%
[Analyst] Revisions Ratio: +16% (up=17, down=12)